- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00658047
A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis (CH-1504-201)
A Phase II, Multi-center, Randomized, Double-blind, Methotrexate Controlled Study to Assess the Clinical Efficacy, Safety, and Tolerability of CH-1504 in Subjects With Active Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rheumatoid Arthritis (RA) is a chronic inflammatory disease of unknown cause that leads to pain, stiffness, swelling and limitation of joint function. If left untreated, RA produces serious destruction of joints that frequently leads to permanent disability.
Methotrexate (MTX) is currently the most commonly prescribed first-line disease modifying anti-rheumatic drug (DMARD) because of its early onset of action, good efficacy, and ease of administration. In addition, MTX can be combined with other FDA approved DMARDs, including gold compounds, sulfasalazine, hydroxychloroquine, TNF inhibitors, anakinra and leflunomide. However, the administration of MTX has been associated with serious side effects such as skin reactions, pneumonitis, gastrointestinal disturbances including diarrhea, ulcerative stomatitis and hemorrhagic enteritis, hepatotoxicity and renal toxicity. Overall it is estimated that up to 30% of all patients discontinue MTX therapy due to side effects.
MTX enters cells via the Reduced Folate Carrier (RFC) system. Once inside cells, it is converted enzymatically to polyglutamylated derivatives. These metabolites cannot be readily effluxed and are retained in tissues. The accumulation of polyglutamyl metabolites of MTX for prolonged periods may play a significant role in both the efficacy and the toxicity of this compound. Methotrexate in its parent form only has activity against dihydrofolate reductase (DHFR). In order for it to have significant activity against other enzymes (i.e. Thymidylate Synthase (TS)) it must be polyglutamylated. However by being polyglutamylated the MTX metabolite is retained in the cell and may potentiate the cytotoxicity of MTX. In addition to polyglutamylation metabolism, MTX is also hydroxylated in the liver to a metabolite known as 7-hydroxymethotrexate, which is also subject to polyglutamylation and cell retention. This metabolite has been implicated in liver and kidney toxicity of the parent compound, while contributing no role in efficacy.
CH-1504 has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is MTX. CH-1504 has significant activity on both DHFR and TS enzymes without the need for polyglutamylation. The lack of hydroxylation potentially leads to enhanced levels of the active drug in the cell. Furthermore, the glutamyl moiety is not susceptible to being cleaved by carboxypeptidase. Thus CH-1504 may be referred to as a metabolically stable antifolate. It is our hypothesis that in the clinical setting CH-1504 will demonstrate the efficacy of classical antifolates (via folate enzyme inhibition) but will be devoid of the toxicity secondary to the formation of the polyglutamylated and hydroxylated metabolites, providing a significantly improved therapeutic index compared to classical antifolates, such as MTX.
This study is a randomized, double-blind, methotrexate controlled study to assess the clinical effect of CH-1504 in patients with active rheumatoid arthritis by determining the proportion of patients achieving an ACR20 response after 12 weeks of treatment.
Secondary objectives are:
- Assess the clinical efficacy of CH-1504 by proportion of patients achieving ACR50 and ACR70 responses.
- Assess the clinical efficacy of CH-1504 using EULAR "good" and "moderate" response criteria.
- Assess the clinical efficacy of CH-1504 using the difference from baseline of ACR core set and DAS28 of measures.
- Evaluate the safety and tolerability of CH-1504 in RA patients as determined by the frequency and severity of adverse events, laboratory abnormalities, and dropouts.
- Identify the dose response relationship of CH-1504
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion; To be eligible for inclusion, each patient must fulfill the following criteria:
- Patients must be between the ages of 18 and 80;
- Have been diagnosed with active rheumatoid arthritis according to ACR criteria;
- Have at least 6 swollen joints (max = 66) and 6 tender joints (max = 68) at screening and baseline visits;
- Patients must have at least one of the following:
- C-reactive protein > 1.0 mg/dl at screening;
- erythrocyte sedimentation rate > 20 mm/Hr;
- Morning stiffness > 45 min. at screening;
- Patients must have blood test values per the following criteria:
- ALT, AST < 1.2 U/l x ULN
- Albumin > 2.5 g/dl
- Prothrombin Time < 1.2 INR
- Hb > 9.0 g/dl
- Hct > 35%
- WBC > 3000 μl (mm3)
- Neutrophils > 1000 μl (mm3)
- Platelets > 100000 μl
- Creatinine < 1.2 mg/dl
- Patients must have voluntarily signed the informed consent
Exclusion; Patients are not eligible for this study if they fulfill one or more of the following criteria:
- Patients who received previous methotrexate therapy;
- Patients who received previous therapy with any biologic agent;
- Previous biologic therapy for a disease other than RA is permitted so long as their last dose was more than 120 days prior to baseline;
- Patients currently taking sulfasalazine;
- Previous sulfasalazine therapy is permitted so long as their last dose was more than 30 days prior to baseline;
- Patients currently taking hydroxychloroquine;
- Previous hydroxychloroquine is permitted so long as their last dose was more than 120 days prior to baseline;
- Female patients of child bearing potential who are pregnant or who are not using two methods of contraception (at least one barrier: i.e. condom) with their partner;
- Male patients who are sexually active and not using two methods of contraception (at least one barrier: i.e. condom) with their partner;
- Patients with any current active infection or infections requiring IV drug therapy within 30 days of baseline or oral therapy within 15 days of Baseline;
- Patients that have had any surgical procedures within 30 days of baseline;
- Patients with a history of HIV, Hepatitis B or C;
- Patients who consume more than 7 units of alcohol per week (1 unit = 5 ounces/150 ml of wine = 1.5 ounces/45 ml spirits = 12 ounces/360 ml of beer);
- Patients currently receiving any investigational drug or have received an investigational drug within 30 days of baseline or 5 half-lives of the investigational drug (whichever is longer);
- Patients with a history of cancer within the past 5 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ;
- Patients with a history of, or any, disease associated with an inflammatory arthritis other than RA;
- Patients with a chest X-ray that indicates the presence of pulmonary fibrosis (Chest x-ray may be taken with in 28 days of screening);
- Patients receiving Probenecid;
- Patients who have received any steroid injections within 30 days of baseline;
- Patients with concomitant diseases that are unstable (i.e. cardiac, pulmonary) or that may affect drug activity (i.e. absorption, reactions, change in kinetics);
- Patients considered by the investigator to be an unsuitable candidate to receive CH-1504;
- Wheelchair or bed-bound patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.25 mg CH-1504
|
Comparison of different doses of CH-1504
|
Experimental: 0.5 mg CH-1504
|
Comparison of different doses of CH-1504
|
Experimental: 1.0 mg CH-1504
|
Comparison of different doses of CH-1504
|
Active Comparator: Methotrexate
Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
|
10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the clinical effect of CH-1504 (0.25, 0.5, and 1.0 mg po daily) by determining the proportion of patients achieving an ACR20 response.
Time Frame: 3 months of treatment
|
3 months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the clinical efficacy of CH-1504 by proportion of patients achieving ACR50 and ACR70 responses.
Time Frame: 3 months of treatment
|
3 months of treatment
|
Assess the clinical efficacy of CH-1504 using EULAR "good" and "moderate" response criteria.
Time Frame: 3 months of treatment
|
3 months of treatment
|
Assess the clinical efficacy of CH-1504 using the difference from baseline of ACR core set and DAS28 of measures.
Time Frame: 3 months of treatment
|
3 months of treatment
|
Evaluate the safety and tolerability of CH-1504 in RA patients as determined by the frequency and severity of adverse events, laboratory abnormalities, and dropouts.
Time Frame: 3 months of treatment
|
3 months of treatment
|
Identify the dose response relationship of CH-1504.
Time Frame: 3 months of treatment
|
3 months of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Edward Keystone, MD, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- CH-1504-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
David Grant U.S. Air Force Medical CenterCompleted
-
TcLand Expression S.A.European CommissionTerminatedRheumatoId ArthritisFrance, Netherlands, Turkey, Czechia, Israel
Clinical Trials on CH-1504
-
Manuela EicherSwiss Cancer League; Lindenhofgruppe AGCompletedBreast Neoplasm | Self-Management | Intervention | Cancer Survivorship | Early-Stage Breast CancerSwitzerland
-
Fundació Institut de Recerca de l'Hospital de la...European Clinical Research Infrastructure Network; Asociacion Colaboracion...TerminatedUrinary Tract InfectionSpain, Portugal, Chile, Italy, Turkey
-
University Hospital, GrenobleTerminated
-
Centre hospitalier de l'Université de Montréal...Not yet recruitingOlder Adults | Nursing | Healthy Lifestyle Habits | Web-based Intervention
-
University of PittsburghNational Institute of Mental Health (NIMH); Northwestern UniversityCompleted
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University)CompletedPreterm Infants | Infant, Low Birth WeightIndia
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA); University of ArkansasCompleted
-
Laboratorios Leti, S.L.CompletedRhinitis, Allergic, Seasonal | Conjunctivitis, AllergicSpain
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)Completed